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Background: Radiofrequency ablation of saphenous veins has proven efficacy with an excellent side effect profile but has
the disadvantage of a lengthy pullback procedure. This article reports a new endovenous catheter for radiofrequency-
powered segmental thermal ablation (RSTA) of incompetent great saphenous veins (GSVs).
Methods: A prospective, nonrandomized, multicenter study was conducted to evaluate the safety, feasibility, and early
clinical outcomes of RSTA of the GSV.
Results: A total of 194 patients with 252 GSVs with an average diameter of 5.7  2.2 mm (range, 2.0 to 18.0 mm)
received RSTA under tumescent local anesthesia. In 58 patients (29.9%), bilateral treatment (average length treated, 36.7
 10.8 cm) was done. The average total endovenous procedure time was 16.4 8.2 minutes, and the average total energy
delivery time was 2.2  0.6 minutes. The corresponding endovenous fluence equivalent delivered to the proximal 7-cm
vein segment was 82  25 J/cm2 (range, 38 to 192). Follow-up at 3 days, 3 months, and 6 months was obtained from
250, 164, and 62 limbs, respectively. Occlusion rates were 99.6% for all three follow-up dates according to life-table
analysis. The average Venous Clinical Severity Score was 3.4  1.2 at 3 days, 0.9  1.6 at 3 months, and 1.5  1.8 at 6
months compared with 3.9  2.0 at baseline.
Conclusion: Radiofrequency segmental thermal ablation is feasible, safe, and well tolerated. (J Vasc Surg 2008;47:
151-6.)Endovenous thermal ablation techniques, which in-
clude radiofrequency ablation (RFA) or endovenous laser
treatment (ELT), are less invasive treatment options as an
alternative to high ligation and stripping of the incompe-
tent great saphenous vein (GSV), and the mid-term results
of RFA and ELT suggest that endovenous thermal ablation
techniques are at least as effective and durable as traditional
saphenous vein surgery.1-4 Furthermore, the superiority of
endovenous thermal ablation over high ligation and strip-
ping in terms of return to normal physical activity has been
indicated in randomized trials.5-7
RFA and ELT differ significantly in their mode of
action of delivering thermal energy to the vein wall. Laser
energy is delivered endovenously from the fiber tip and is
highly focused, with temperatures of 100°C close to the
fiber tip.8 RFA operates by resistive heating of the vein wall
in its whole circumference, causing endovenous tempera-
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doi:10.1016/j.jvs.2007.08.056tures of 85° to 90°C. As a result of the high temperature
and the focused nature of the laser beam, ELT, unlike RFA,
is generally associated with vein wall perforations.8,9 This is
one of the reasons why ELT is associated with more treat-
ment-related pain and indurations during the patient re-
covery phase compared with RFA.10 However, the mode of
action of RFA causes also a significantly prolonged ablation
time if compared with ELT.
To overcome the disadvantage of slower treatment but
to keep the advantage of fewer side effects in the post-
treatment interval, a new radiofrequency powered catheter
using the principle of segmental thermal ablation was de-
veloped. This article reports the first clinical experience in
194 patients and 252 limbs treated with this novel treat-
ment modality.
METHODS
Patients. The patients were an average  SD age of
50.5 13.6 years (range, 18 to 80 years), and 144 (74.2%)
were women. Patient comorbidities were moderate; the
most frequent were hypertension in 35 (18%) and thyroid
disease in 19 (9.8%). Less frequent were cardiovascular
disease in 3 (1.5%), peripheral arterial disease in 2 (1.0%),
arthritis in 3 (1.5%), diabetes mellitus in 7 (3.6%), and
severe obesity (body mass index 30) in 1 (0.5%).
The pretreatment maximum CEAP clinical class distri-
bution is summarized in Table I. C3 or lower class com-
prised 82.1% of limbs. The average preprocedure Venous
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1 to 11). To detect potential influences of the vessel geom-
etry on the efficacy of the study treatment, the anatomy of
the saphenofemoral junction (SFJ) was classified as funnel
shape in 47.2%, cylinder shape in 37.3%, or bulbous in
14.3% of limbs. Pretreatment vein diameters measured in
the supine position at 3 cm distal to the SFJ averaged 5.7
2.2 mm (range, 2.0 to 18.0 mm).
Study design. This prospective, nonrandomized,
multicenter study evaluated the feasibility, safety, and early
clinical outcomes of RSTA of the GSV in patients with
chronic venous disease. Study treatments were performed
at eight different clinical sites in Germany and France after
approval by local authorities and the local ethical review
boards according to theDeclaration ofHelsinki and its later
extensions. The study sites were selected by the study
sponsor because of their substantial experience in en-
dovenous thermal ablation. The centers received free cath-
eters and technical equipment for treatment of study pa-
tients.
Data storage and data monitoring were also provided
by the study sponsor. Authors had access to any of these
data as requested for analysis and interpretation of study
results. Written informed consent was obtained from all
patients enrolled in the study, and clinical data were col-
lected on standardized case report forms.
Inclusion criteria. Patients of different clinical stages
of chronic venous disease and reflux in the GSV demon-
strated by duplex ultrasound (DUS) imaging were candi-
dates for study treatment and were further screened for
study enrollment. Significant GSV reflux was defined as
reflux duration of 500 ms after the Valsalva maneuver or
distal augmentation while the patient was standing or in
reverse Trendelenburg position. Reflux had to be demon-
strated continuously from the SFJ down to the distal point
of reflux. Large vein diameters were not an exclusion crite-
rion for study enrollment Additional inclusion criteria for
enrollment into the study were age 18 to 80 years, a general
physical condition allowing for frequent ambulation after
the procedure, and availability to complete the follow-up
visits according to the study protocol. Patients who were
pregnant, breast-feeding, or who had evidence of old or
fresh thrombus in the vein segment to be treated were
excluded from study enrollment.
Patient follow-up. During an initial phase of the
Table I. Preprocedure maximum CEAP clinical class
distribution
CEAP category No. (%)
Data missing 2 (0.8)
CEAP 1 2 (0.8)
CEAP 2 132 (52.4)
CEAP 3 73 (29.0)
CEAP 4 41 (16.3)
CEAP 5 1 (0.4)
CEAP 6 1 (0.4)study, patients (71 limbs) were followed up at 72 hours, 3weeks, 3 months, and 6 months. After an interim analysis
on treatment outcomes and side effects, the 3-week visit
was found to be uninformative and was discontinued. Each
follow-up visit consisted of clinical examination, the com-
pletion of a questionnaire and DUS examination of the
treated limb in the reverse Trendelenburg position.
The primary study end points were occlusion of and
lack of reflux in the treated vein. Vein occlusion was defined
as absence of any flow from 3 cm inferior to the SFJ along
the whole length of the treated vein. The 3-cm limit was
selected representing the occlusion status of the proximal
GSV and furthermore allowed precise evaluation with a
typical 4-cm-length linear ultrasound probe. Lack of reflux
had to be proved by DUS imaging using the mentioned
criteria along the whole vein segment treated.
Secondary end points included the evaluation of side
effects, adverse events, clinical outcomes, and patient re-
covery after the treatment. Patient symptoms and signs
were recorded using CEAP clinical classification and
VCSS.11,12 The side effects and complications associated
with the procedure were recorded and analyzed. Postpro-
cedural pain and tenderness were evaluated using an analog
scale, with the minimum of 0 representing no pain and a
maximum of 10 representing worst possible pain. The
analog scale was used in a nonvisual fashion after explaining
it to the patient. Tenderness represented the discomfort
level in responding to touch or palpation and was also
measured using the analog scale between 0 and 10.
Statistical analysis. Baseline characteristics such as
demographics, medical history, and venous symptoms were
summarized using descriptive statistics. End point analysis
was performed at each follow-up. Measurable parameters
were expressed as mean  SD, and proportions were ex-
pressed as percentages and 95% confidence intervals. Data
were analyzed on per-patient or per-limb, as appropriate.
Patients with bilateral treatment were treated as one for
data analyzed by subject. For data analyzed on a by limb,
the two limbs were treated separately. Descriptive statistics
was performed using Excel software (Microsoft Inc, Red-
mond, Wash).
Study device and procedure. A segmental heating
catheter of 7F diameter (ClosureFAST catheter, VNUS
Medical Technologies Inc, San Jose, Calif) consisting of a
7-cm heating element covered with lubricious material, an
integrated handle, and cable that connected to the VNUS
RFGPlus generator was used. The thermal element con-
sisted of a coil that was heated by a 460 kHz AC current to
a temperature of 120°C during treatment cycles with a
20-second duration. A thermocouple on the heating ele-
ment provided a feedback loop to the generator to adjust
the generator output power to achieve and maintain the
120°C temperature.
The procedure was totally performed under ultrasound
guidance. Vein access was achieved through puncture or
venae sectio at the distal point of reflux, but to confine
study treatment to the portion that ran within its fascial
sheath. A 0.025-inch guidewire and a dilator were used to
place an introducer sheath of 7F diameter and 11 cm in
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lumen of the catheter was flushed with heparinized saline
and capped. The catheter tip was then advanced through
the introducer sheath just inferior to the ostium of the
superficial epigastric vein, or at least 1 to 2 cm below the
SFJ if the superficial epigastric vein was not visible. In
situations where the patient presented with tortuous or
unusual vein anatomies, external leg manipulation or an
optional 0.025-in guidewire (150-cm wire for the 60-cm
catheter or a 260-cm wire for the 100-cm catheter) could
be used to facilitate catheter advancement and placement.
The leg was elevated to an angle of about 20° to 30°,
and perivenous tumescent fluid was injected manually or by
use of a pump along the vein, not only to control treatment-
related pain but also to reduce the diameter of the vein and
in the same instance protect surrounding tissue from heat
damage. After confirmation that the vein was adequately
compressed circumferentially and that the depth of the vein
was at least 1 cm below the skin surface, the final catheter
tip position was verified and radiofrequency segmental
thermal ablation (RSTA) treatment was started under con-
tinuous ultrasoundmonitoring. With external compression
provided by the ultrasound probe and an additional finger-
tip, 20-second heating cycles were delivered. In the initial
catheter position near the SFJ, a second treatment cycle was
applied to increase energy dosing in this critical area. The
catheter was then repositioned to the adjacent segment
guided by shaft markers in 6.5-cm steps to allow a 5-mm
overlap of heated vein segments. After the first segment,
each successive segment was treated for only one cycle,
except in the case of aneurysmal segments or near large
tributaries where a second cycle might be administered at
the user’s discretion.
Toward the end of the treatment, the marker on the
sheath indicates when the heating coil begins to enter the
sheath and the treatment should be terminated (Fig 1).
After the last treatment cycle, the catheter and sheath were
removed from the vein and the access site was closed, if
Fig 1. Sheath marker indicates last treatment segment.necessary.After treatment, the entire length of the treated vein
was assessed using DUS to determine vein occlusion, even-
tual reflux, and vein wall thickening. Post-treatment diam-
eters of the treated vein were recorded at 3 cm and 15 cm
below the SFJ, representing the proximal and middle thigh
location, respectively. Procedure variables, treatment time,
and any unique anatomy, side effects, or treatment events
were also recorded. Linear endovenous energy density
(LEED) and endovenous fluence equivalent (EFE) were
calculated as already described elsewhere.2,13 These mea-
sures, originally described for ELT, were used in an analo-
gous fashion to describe the endovenous energy delivery of
the study device.
Excentric compression was applied for 24 to 72 hours
by means of plaster-fixed gauze over the course of the
treated vein. Graduated stockings with a maximum com-
pression of 30 mm Hg were recommended for 1 week.
During the initial phase after treatment, this double-
compression treatment should allow ideal selective com-
pression of the treated vein. After the intervention, patients
were immediately mobilized and advised to ambulate reg-
ularly. Nonsteroidal anti-inflammatory drugs were pro-
vided to the patients as needed.
RESULTS
From April to November 2006, 194 patients (252
limbs) were treated at eight sites in Germany and France; of
these, 58 (29.9%) had bilateral treatments. In 48 patients,
both limbs were treated in the same session, and 10 re-
ceived the treatment of their other limb during a second
treatment session.
Concomitant procedures. Thirty of 252 limbs had
undergone previous venous interventions, including vein
stripping in 3, ligation in 1, ELT and phlebectomy in 1,
RFA in 1, RFA and sclerotherapy in 1, phlebectomy, scle-
rotherapy in 15, and 1 was unspecified. Despite any pre-
treatment modality, however, all limbs showed a typical
nonoccluded incompetent GSV at the time of study treat-
ment. Additional treatments performed at the time of the
study procedure were phlebectomy in 71.4% limbs and
foam sclerotherapy of tributaries in 13.9%. In one limb, the
incompetent anterior accessory saphenous vein was treated
with the segmental thermal ablation catheter concomi-
tantly with the GSV ablation. During the study follow-up
period, one additional limb had phlebectomy and 18 limbs
received sclerotherapy for persisting varicose tributaries;
however, how much—or if at all—these adjuvant measures
contributed to the good reported occlusion rates remains
unclear.
Delivery of thermal energy. The total average en-
dovenous procedure timemeasured from catheter insertion
to catheter removal, including the time for the administra-
tion of tumescent anesthesia, was 16.4  8.2 minutes.
Total average energy delivery time during segmental ther-
mal ablation was 2.2 0.6minutes (range, 1 to 4minutes).
Patients were treated with an average of 6.7  1.7 thermal
ablation cycles, and the average vein length treated was
36.7  10.8 cm.
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limbs treated during the early phase of the study. The
average linear endovenous energy density delivered was
116.2 11.6 J/cm (range, 71.4 to 143.3 J/cm) along the
proximal 7-cm vein segment next to the SFJ and 68.2 
17.5 J/cm (range, 17.3 to 132.7 J/cm) along the remain-
der of the vein. Even more interesting, the endovenous
fluence equivalent (EFE) calculated from the same data set
at 3 cm distal to the SFJ was as high as 82  25 J/cm2
(range, 38 to 192 J/cm2).
Ultrasound findings. Immediate vein occlusion after
segmental thermal ablation with lack of spontaneous and
augmented flow demonstrated by ultrasound was achieved
in 100% of the treated veins. Vein wall thickening was
evident immediately after treatment in 100% of the treated
limbs.
The number of limbs due for follow-up and the num-
ber of limbs that had follow-up are presented in Table II.
The vein-occlusion and reflux-free rates according to the
Kaplan-Meier method were all 99.6% at 3 days, 3 months,
and 6 months. The patent stump length was 1.5  0.7 cm
at the SFJ at 6 months. A subset of 71 limbs had 3-week
follow-up data that contributed no relevant additional in-
formation.
One vein exhibited flow after augmentation and reflux
along the entire treated segment despite a narrowed lumen
at the DUS examination on day 3. A large anterior acces-
sory GSV was connected to the treated vein and exhibited
reflux. This vein was occluded at the 3-month follow-up.
One other GSV that was occluded at the 3-day follow-up
showed segmental flow without reflux at the middle to
lower thigh at 3 weeks and was occluded at the 3-month
follow-up.
Vein diameters 3 cm inferior to the SFJ were docu-
mented at each DUS examination, and a progressive vein
diameter reduction was evident, as demonstrated in Fig 2.
For the limbs with follow-up data at 6months, treated veins
decreased in diameter size by 19.9% at 3 days, 26.6% at 3
months, and 43.5% at 6 months compared with the prepro-
cedural vein diameter (P  .001, paired t test).
Clinical response and side effects. Significant patient
symptom relief was observed as early as 3 days after the
procedure. Limb pain, which was reported in 57.5% of
limbs before treatment, decreased to 10.8% at the 3-day
follow-up visit (P .001, 2 test). The percentage of limbs
Table II. Treatment efficacy
Variable Treat
Limbs due for follow-up, No. 25
Limbs with data available (limbs at risk), No. (%) 252 (
Patients due for follow-up, No. 19
Patients with data available, No. (%) 194 (
Vein occlusion rate per limb, %* 10
Reopened veins, No.
*Kaplan-Meier method.with edema decreased from 52.8% preoperatively to 3.2% at3 days (P .001, 2 test). The average VCSS score was 3.4
 1.2 at 3 days, 0.9  1.6 at 3 months, and 1.5  1.8 at 6
months compared with 3.9  2.0 preoperatively. It may,
however, be true that a part of the improvement of edema
and VCSS was due to the consequent wearing of compres-
sion stockings. Although stockings were used on 72 of 252
limbs (28.2%) before the intervention, stockings were worn
after GSV ablation on 244 limbs (97%) at 3 days, 23 (14%)
at 3 months, and 6 (9.7%) at 6 months.
Return to normal daily activities took place on the same
day in more than half of patients, with an average  SD of
1.0  1.9 days (median, 0 days; range, 0 to 17 days).
Serious complications such as deep venous thrombosis
or thermal skin injury were not observed in any study
subject. Paresthesia occurred as localized patches in eight
treated limbs (3.2%) during the follow-up period at the
medial middle thigh region above the course of the GSV.
Two limbs (0.8%) showed thrombophlebitis characterized
by pain sensation and a visible reddening along the course
of the treated GSV. Sole erythema was noticed in four more
cases. Ecchymosis along the course of the treated GSV was
present in 16 limbs after study treatment. Hematoma,
defined as a three-dimensional ultrasound-detectable inter-
stitial clot, was noticed in four limbs at the puncture site 3
days after the procedure. Skin pigmentation in the course of
phlebitis or ecchymosis developed in five limbs (Table III).
Patients evaluated postprocedural pain on a scale of 0
3 days 3 months 6 months
252 198 74
250 (99.2) 164 (82.8) 62 (83.8)
194 163 62
194 (100) 132 (81.0) 53 (85.5)
99.6 99.60 99.60
1 0 0
Fig 2. Average vein diameter reduction after the treatment. The







0(no pain) to 10 (worst possible pain) and 70.1% of limbs
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average pain score was 0.7 1.6 during the first 3 days. For
patients who experienced limb pain at anytime during the
follow-up period, the maximum pain score was 2.8  1.6.
Tenderness in response to the treatment was evaluated in
similar fashion, and 67.7% of limbs experienced no tender-
ness at any time after the procedure. For the limbs that
experienced tenderness, the maximum score was 1.9 1.2.
Patient satisfaction was high: 192 of 194 patients (99.0%)
would recommend the procedure to friends or relatives.
DISCUSSION
Ample clinical data have been accumulated in last sev-
eral years on endovenous thermal ablation procedures,
namely RFA and ELT. More recently, the concept of
energy dosing during endovenous thermal ablation was
recognized. With RFA, it was clear from the beginning that
the catheter pullback velocity had to be slow enough to
allow resistive heating of the vein wall to a target tempera-
ture of 85° to 90°C. However, because the radiofrequency
power delivered by the generator was subject to regulation
by a feedback loop to keep a constant temperature of 85°C
at the catheter tip, measurements of the delivered energy
dose to the vein were not possible under routine clinical
conditions. With ELT, finally, parameters have been intro-
duced describing the amount of delivered energy along the
vein (LEED) or with respect to the inner vein wall surface
(EFE).13 These parameters were determined in an analog
fashion for ELT during the initial phase of this study and
also with the new segmental thermal ablation catheter. The
EFE at the first treatment segment was as high as 82  25
J/cm2, comparable or even exceeding the EFE values
reported with ELT.
The LEED is also a parameter frequently used to com-
pare energy dosing in endovenous procedures. Timperman
et al14,15 reported that 80 J/cm is required to achieve
satisfactory treatment efficacy. With the ClosureFast proce-
dure, an average of 116.2  11.6 J/cm was delivered for
the first 7 cm of vein near the SFJ to ensure good vein
occlusion at this critical location. For the remainder of the
vein, the energy dose delivered was 68.2  17.5 J/cm.
As a consequence of this sufficient energy dose, a 100%
ablation of reflux was achieved immediately after the pro-
cedure. With one single open vein at 3 days, life-table
analysis resulted in an occlusion rate of 99.6% at 3 days, 3
months, and 6 months after the intervention. If a brief
Table III. Complications after the procedure






Hyperpigmentation 5 2.0comparison of clinical outcomes at this early stage is possi-ble at all, it may be worth stressing this significantly higher
short-term occlusion rate after segmental thermal ablation
compared with RFA, which was usually described at about
95%.5,16 The number of limbs at risk, however, was still
small at the 6-month follow-up (Table II). Of most interest
was that despite this high dosing of thermal energy, the
favorable side effect profile of RFA was also demonstrated
after segmental thermal ablation.
An initially pronounced and later sustained progressive
shrinkage of the occluded veins may be another surrogate
marker of long-term durability of segmental thermal abla-
tion. During study follow-up, this was observed by ultra-
sound examination, with 19.9% vein diameter reduction as
early as 3 days and 43.5% by 6 months. A few of the veins
were already not identifiable by 6 months.
Another factor that may also have contributed to the
excellent treatment efficacy of segmental thermal ablation
was the simplicity and reproducibility of catheter pullback.
Unlike the previous RFA and ELT techniques, segmental
ablation is associated with a catheter that remains stationary
during energy delivery. This technique avoids pullback
speed variability, which can result in variable and insuffi-
cient energy dosing and thus result in inadequate treat-
ment. Furthermore, the temperature is kept stable at
120°C during a 20-second treatment cycle, thus avoiding
peak temperatures of several hundred degrees as seen with
ELT ablation. This controlled heating avoids vein perfora-
tions with unintended heat damage of perivenous tissue;
thus, even with high dosing of thermal energy, the proce-
dure was well tolerated by the patients.
Patients reported no pain in 70% of their limbs at
anytime after the procedure. After ELT, one can generally
expect70% of limbs experience some degree of pain, and
50% require analgesics for pain management.2 Kabnick17
reported an average pain score of 2.2 to 2.6 on a scale of 0
to 5 after ELT.
Ecchymosis, which was observed in 6.4% limbs, was
likely due to tumescent anesthesia. The incidence of phle-
bitis was 0.1% and paresthesia, 2.8%. This compares very
favorably with the reported patient recovery profile after
ELT. Ecchymosis can occur in 70% of limbs treated with
ELT, likely due to vein perforation by laser energy and
sometimes tumescent anesthesia.2,5 Thrombophlebitis
rates of 5% to 33.3% have been reported after ELT.3,12 The
occurrence of paresthesia was reported at 5% to 12% with
ELT2 and previous RFA.1
With the previous RFA catheter, the slow pullback
speed and the occasional need for removing the catheter to
clean off the coagulum on the electrodes during the proce-
dure were two disadvantages compared with ELT. The
ClosureFast catheter completely eliminates the pullback.
The average energy delivery time was 2.2  0.6 minutes.
To factor in other procedure steps such as tumescent infil-
tration and catheter repositioning, the procedure time from
catheter insertion to catheter removal was 16.4  8.2
minutes. This includes the learning curve and tedious ul-
trasound observation and documentation during the initial
cases. The elimination of pullback, the short energy cycle,
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rapid treatment and dramatically simplified the procedure.
This study has some limitations. It only includes early
clinical experiences from a limited number of users and only
has short-term data available. Also, a control group is
lacking within this study, which was focused at first on
feasibility and safety. Some interesting conclusions, how-
ever, should be possible from long-term follow-up, which is
currently in progress. With a wider adoption of this proce-
dure, a variety of procedural techniques and settings could
potentially affect the consistent results seen in this con-
trolled, clinical trial setting.
CONCLUSION
Radiofrequency powered segmental thermal ablation
proved to be a fast and safe procedure with close to 100%
early occlusion rate of treated GSVs. Despite delivering
high doses of thermal energy the method was well tolerated
by the patients, who showed an insignificant side effect
profile.
AUTHOR CONTRIBUTIONS
Conception and design: TP
Analysis and interpretation: TP
Data collection: TP, BV JA, OG, CW, CL, OP, CS, CGS,
TN, DC
Writing the article: TP
Critical revision of the article: TP, BV JA, OG, CW, CL,
OP, CS, CGS, TN, DC
Final approval of the article: TP, BV JA, OG, CW, CL, OP,
CS, CGS, TN, DC
Statistical analysis: TP, BV JA,OG, CW,CL,OP, CS, CGS,
TN, DC




1. Merchant RF, Pichot O; the Closure Study Group. Long-term out-
comes of endovenous radiofrequency obliteration of saphenous reflux as
a treatment for superficial venous insufficiency. J Vasc Surg 2005;42:
502-9.
2. Proebstle TM, Moehler T, Herdemann S. Reduced recanalization rates
of the great saphenous vein after endovenous laser treatment with
increased energy dosing: definition of a threshold for the endovenous
fluence equivalent. J Vasc Surg 2006;44:834-9.
3. Min RJ, Khilnani N, Zimmet SE. Endovenous laser treatment of
saphenous vein reflux: long-term results. J Vasc Interv Radiol 2003;14:
991-6.
4. Sharif MA, Soong CV, Lau LL, Corvan R, Lee B, Hannon RJ. En-
dovenous laser treatment for long saphenous vein incompetence. Br J
Surg 2006;93:831-5.
5. Lurie F, Creton D, Eklof B, Kabnick LS, Kistner RL, Pichot O, et al.
Prospective randomised trial of endovenous radiofrequency obliteration(closure) versus ligation and stripping (EVOLVeS): two year follow-up.
Eur J Vasc Endovasc Surg 2005;29:67-73.
6. Rautio T, Ohinmaa A, Perälä J, Ohtonen P, Heikkinen T, Wiik H, et al.
Endovenous obliteration versus conventional stripping operation in the
treatment of primary varicose veins: a randomized controlled trial with
comparison of costs. J Vasc Surg 2002;35:958-65.
7. Hinchliffe RJ, Ubhi J, Beech A, Ellison J, Braithwaite BD. A prospective
randomised controlled trial of VNUS Closure versus surgery for the
treatment of recurrent long saphenous varicose veins. Eur J Vasc Endo-
vasc Surg 2006;31:212-8.
8. Weiss RA. Comparison of endovenous radiofrequency versus 810 nm
diode laser occlusion of large veins in an animal model. Dermatol Surg
2002;28:56-61.
9. Proebstle TM, Lehr HA, Kargl A, Espinola-Klein C, Rother W, Bethge
S, et al. Endovenous treatment of the greater saphenous vein with a
940-nm diode laser: thrombotic occlusion after endoluminal thermal
damage by laser-generated steam bubbles. J Vasc Surg 2002;35:729-
36.
10. Proebstle TM, Gul D, Lehr HA, Kargl A, Knop J. Infrequent early
recanalization of greater saphenous vein after endovenous laser treat-
ment. J Vasc Surg 2003;38:511-6.
11. Rutherford RB, Padberg FT Jr, Comerota AJ, Kistner RL, Meissner
MH, Moneta GL. Venous severity scoring: An adjunct to venous
outcome assessment. J Vasc Surg 2000;31:1307-12.
12. Kistner RL, Eklof B, Masuda EM. Diagnosis of chronic venous disease
of the lower extremities: The “CEAP” classification. Mayo Clinic Proc
1996;71:338-45.
13. Proebstle TM, Krummenauer F, Gul D, Knop J. Nonocclusion and
early reopening of the great saphenous vein after endovenous laser
treatment is fluence dependent. Dermatol Surg 2004;30:174-8.
14. Timperman PE. Prospective evaluation of higher energy great saphe-
nous vein endovenous laser treatment. J Vasc Interv Radiol 2005;16:
791-4.
15. Timperman PE, Sichlau M, Ryu RK. Greater energy delivery improves
treatment success of endovenous laser treatment of incompetent saphe-
nous veins. J Vasc Interv Radiol 2004;15:1061-3.
16. Merchant RF, DePalma RG, Kabnick LS. Endovascular obliteration of
saphenous reflux: a multicenter study. J Vasc Surg 2002;35:1190-6.
17. Kabnick LS. Outcome of different endovenous laser wavelengths for
great saphenous vein ablation. J Vasc Surg 2006;43:88-93.
Submitted Mar 30, 2007; accepted Aug 31, 2007.
Appendix
The members of the Closure Fast Study Group are
Thomas Michael Proebstle, MD, MSc, and Bernadette
Vago, MD, Department of Dermatology, University of
Heidelberg, Germany; Jens Alm, MD, Dermatologikum,
Hamburg, Germany; Oliver Göckeritz, MD, and Chris-
tian Wenzel, MD, Venenzentrum am Elsterpark,
Leipzig, Germany; Christian Lebard, MD, Hospital St.
Michel, Paris, France; Olivier Pichot, MD, and Carmine
Sessa, MD, CHU Service de Chirurgie Vasculaire,
Grenoble, France; Claus-Georg Schmedt, MD, Ludwig-
Maximilian Universitaet, München, Germany; Thomas
Noppeney, MD, Gemeinschaftspraxis Nürnberg, Ger-
many; Daniel Creton, MD, Clin Ambroise Paré, Nancy,
France.
JOURNAL OF VASCULAR SURGERY
Volume 47, Number 1 Proebstle et al 156.e1Appendix
Furthermembers of theClosure Fast StudyGroupwere: C.
Wenzel1, C Sessa2, C.G. Schmedt3, T. Noppeney4, D. Creton5
1Venenzentrum am Elsterpark, Leipzig, GERMANY,
2CHU Service de Chirurgie Vasculaire, Grenoble, FRANCE,
3Ludwig-Maximilian Universitaet, Muenchen, GERMANY,
4Gemeinschaftspraxis Nürnberg, GERMANY, 5Clin Am-
broise Paré, Nancy, FRANCE.1Department of Dermatology, University of Heidelberg,
GERMANY, 2Dermatologikum Hamburg, GERMANY,
3Venenzentrum am Elsterpark, Leipzig, GERMANY, 4Hos-
pital St.Michel, Paris, FRANCE, 5CHUService de Chirurgie
Vasculaire, Grenoble, FRANCE, 6Ludwig-Maximilian Uni-
versitaet, Muenchen, GERMANY, 7Gemeinschaftspraxis
Nürnberg, GERMANY, 8Clin Ambroise Paré, Nancy,
FRANCE.
